Company Description
IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications.
The company's development products pipeline consists of PressureSafe, a handheld optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused by prolonged pressure on the sole of the foot and diabetes; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear, a common malady in children.
IR-Med Inc. is headquartered in Rosh Pinna, Israel.
| Country | NY |
| Founded | 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Aharon Klein |
Contact Details
Address: C/o Aboudi Legal Group Pllc, 745 5th Ave, Suite 500 New York, New York 10151 United States | |
| Phone | 6467684285 |
| Website | ir-medical.com |
Stock Details
| Ticker Symbol | IRME |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001839133 |
| ISIN Number | US46265R1032 |
| Employer ID | 84-4516398 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Aharon Klein | Co-Founder, Chief Technology Officer, Interim Chief Executive Officer and Director |
| Oded Bashan | Co-Founder and Chairman |
| Aharon Binur | Chief Development Officer |
| Dr. Yaniv Cohen | Co-Founder, CSO and Director |
| Sharon Levkoviz | Chief Financial Officer |
| Avi Vachnis | Head of Software and AI |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 10, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| Apr 8, 2024 | 10-K/A | [Amend] Annual report |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |